- Email: [email protected]
Sympathomimetic amines as a novel treatment for refractory chronic idiopathic urticaria
437
Sympathomimetic Amines as a Novel Treatment for Refractory Chronic Idiopathic Urticaria
J. H. Check, C. Amadi, H. Kaplan; Dept. OB/GYN, UMDNJ, Robert Wood Johnson Med. School at Camden, Melrose Park, PA. RATIONALE: To corroborate or refute a previous case report showing marked improvement in severe chronic idiopathic urticaria (CIU) by the use of sympathomimetic amines. METHODS: Retrospective review of all patients who were refractory to conventional medication such as various anti-histamines and corticosteroids that were treated with dextroamphetamine sulfate spansules 2030mg/day. The patients were evaluated for degree and persistence of improvement. RESULTS: Four reviewed cases with chronic idiopathic urticaria of a mean 9 years duration (range 4-17 years) showed either moderate to significant improvement following dextroamphetamine sulfate therapy. One patient also had angioedema which also improved considerably following therapy. No cases had to stop using dextroamphetamine sulfate because of side effects. All cases remain improved for treatment duration of 4 years minimum and a maximum of 8 years. CONCLUSIONS: These data corroborate previous findings of 2 previous reported cases that sympathomimetic amines can effectively control chronic idiopathic urticaria that was refractory to conventional therapy. Furthermore, these additional 4 cases show that the effectiveness of therapy does not wane over time. The duration of effectiveness was not evaluated in the 2 previous cases. Also, the therapy was well tolerated. Thus, to date, in a small series of 6 cases, sympathomimetic amine treatment caused significant improvement in 100% of studied cases. A search of the English literature failed to find any publications pro or con about this therapy for CIU in the 20 years since the original publications. Hopefully these data will prompt interest in performing a larger prospective study. Funding: Self-funded
Abstracts S135
SUNDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2
Sympathomimetic Amines as a Novel Treatment for Refractory Chronic Idiopathic Urticaria
J. H. Check, C. Amadi, H. Kaplan; Dept. OB/GYN, UMDNJ, Robert Wood Johnson Med. School at Camden, Melrose Park, PA. RATIONALE: To corroborate or refute a previous case report showing marked improvement in severe chronic idiopathic urticaria (CIU) by the use of sympathomimetic amines. METHODS: Retrospective review of all patients who were refractory to conventional medication such as various anti-histamines and corticosteroids that were treated with dextroamphetamine sulfate spansules 2030mg/day. The patients were evaluated for degree and persistence of improvement. RESULTS: Four reviewed cases with chronic idiopathic urticaria of a mean 9 years duration (range 4-17 years) showed either moderate to significant improvement following dextroamphetamine sulfate therapy. One patient also had angioedema which also improved considerably following therapy. No cases had to stop using dextroamphetamine sulfate because of side effects. All cases remain improved for treatment duration of 4 years minimum and a maximum of 8 years. CONCLUSIONS: These data corroborate previous findings of 2 previous reported cases that sympathomimetic amines can effectively control chronic idiopathic urticaria that was refractory to conventional therapy. Furthermore, these additional 4 cases show that the effectiveness of therapy does not wane over time. The duration of effectiveness was not evaluated in the 2 previous cases. Also, the therapy was well tolerated. Thus, to date, in a small series of 6 cases, sympathomimetic amine treatment caused significant improvement in 100% of studied cases. A search of the English literature failed to find any publications pro or con about this therapy for CIU in the 20 years since the original publications. Hopefully these data will prompt interest in performing a larger prospective study. Funding: Self-funded
Abstracts S135
SUNDAY
J ALLERGY CLIN IMMUNOL VOLUME 113, NUMBER 2